Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 3,420,000 shares, a decrease of 5.5% from the December 31st total of 3,620,000 shares. Based on an average daily volume of 426,500 shares, the short-interest ratio is currently 8.0 days.
Institutional Investors Weigh In On Ascendis Pharma A/S
A number of institutional investors and hedge funds have recently modified their holdings of ASND. Signaturefd LLC raised its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Legato Capital Management LLC grew its position in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 134 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $30,000. GAMMA Investing LLC increased its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after buying an additional 228 shares during the last quarter.
Analyst Upgrades and Downgrades
ASND has been the topic of several research reports. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wedbush reiterated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.57.
Ascendis Pharma A/S Stock Performance
Shares of ASND stock opened at $130.66 on Friday. The stock has a market capitalization of $7.93 billion, a PE ratio of -16.17 and a beta of 0.65. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock’s fifty day moving average is $133.63 and its 200-day moving average is $132.89.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
See Also
- Five stocks we like better than Ascendis Pharma A/S
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Invest in Blue Chip Stocks
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Options Trading – Understanding Strike Price
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.